Adverse cutaneous reactions to imatinib (STI571) in Philadelphia chromosome-positive leukemias: a prospective study of 54 patients
- PMID: 12582389
- DOI: 10.1067/mjd.2003.44
Adverse cutaneous reactions to imatinib (STI571) in Philadelphia chromosome-positive leukemias: a prospective study of 54 patients
Abstract
Background: Imatinib is a new major treatment in chronic myeloid leukemia.
Objective: To study the cutaneous reactions induced by imatinib.
Methods: All inpatients and outpatients with Philadelphia chromosome-positive leukemia treated by imatinib were included in this prospective study. Clinical features, pathologic findings, evolution of each case, and analysis of potential risk factors were recorded.
Results: A total of 54 patients were included, 48 of whom experienced at least 1 cutaneous reaction. These reactions consisted of 36 rashes, 35 edemas, and 22 pruritus. The rash was severe in 5 patients, resulting in temporary interruption of treatment in 3. Highly significant relationships were observed between the daily dose of imatinib and both rashes and edema. In a multivariate analysis, female sex and the daily dose of imatinib were independent risk factors for the development of rashes.
Conclusion: Adverse cutaneous reactions induced by imatinib are frequent, generally moderate, and dose-dependent.
Similar articles
-
Acute generalized exanthematous pustulosis associated with STI571 in a patient with chronic myeloid leukemia.Dermatology. 2001;203(1):57-9. doi: 10.1159/000051705. Dermatology. 2001. PMID: 11549802
-
A patient of chronic myelogenous leukemia developing painful rash on feet.J Postgrad Med. 2012 Oct-Dec;58(4):331-4. doi: 10.4103/0022-3859.105489. J Postgrad Med. 2012. PMID: 23298941 No abstract available.
-
Severe pustular eruption associated with imatinib and voriconazole in a patient with chronic myeloid leukemia.Dermatology. 2005;211(4):363-5. doi: 10.1159/000088510. Dermatology. 2005. PMID: 16286749
-
Indications for imatinib mesylate therapy and clinical management.Oncologist. 2004;9(3):271-81. doi: 10.1634/theoncologist.9-3-271. Oncologist. 2004. PMID: 15169982 Review.
-
Successful progressive challenge after a cutaneous reaction to imatinib mesylate (Gleevec): a case report and review of the literature.Allergy Asthma Proc. 2004 Sep-Oct;25(5):345-7. Allergy Asthma Proc. 2004. PMID: 15603208 Review.
Cited by
-
Spontaneous reporting of serious cutaneous reactions with protein kinase inhibitors.Eur J Clin Pharmacol. 2013 Oct;69(10):1819-26. doi: 10.1007/s00228-013-1532-6. Epub 2013 Jun 9. Eur J Clin Pharmacol. 2013. PMID: 23748749
-
Imatinib-induced Stevens-Johnsons syndrome.BMJ Case Rep. 2013 Jan 23;2013:bcr2012007926. doi: 10.1136/bcr-2012-007926. BMJ Case Rep. 2013. PMID: 23349042 Free PMC article.
-
Hair disorders in patients with cancer.J Am Acad Dermatol. 2019 May;80(5):1179-1196. doi: 10.1016/j.jaad.2018.03.055. Epub 2018 Apr 14. J Am Acad Dermatol. 2019. PMID: 29660422 Free PMC article. Review.
-
Possible Role of Interleukin-31/33 Axis in Imatinib Mesylate-Associated Skin Toxicity.Turk J Haematol. 2015 Jun;32(2):168-71. doi: 10.4274/tjh.2014.0021. Turk J Haematol. 2015. PMID: 26316486 Free PMC article.
-
Oral and cutaneous lichenoid eruption with nail changes due to imatinib treatment in a chinese patient with chronic myeloid leukemia.Ann Dermatol. 2015 Apr;27(2):228-9. doi: 10.5021/ad.2015.27.2.228. Epub 2015 Mar 24. Ann Dermatol. 2015. PMID: 25834373 Free PMC article. No abstract available.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
